Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.

Abstract excerpt

KRAS genes are the most commonly mutated oncogenes in cancer. Unfortunately, effective therapeutic strategies for targeting KRAS mutant cancers have proven to be difficult to obtain. A key reason for this setback is due to the lack of success direct KRAS mutant inhibitors have received. Researchers have turned their efforts away from targeting the KRAS nucleotide-binding site directly and towards targeting other...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Models, Molecular
• Share to Molecular Structure
• Share to Mutation